article thumbnail

Pharmacy Education Must Keep Pace With Changing Health Care Landscape | ACCP 2024

Drug Topics

Posters presented at ACCP 2024 revealed gaps in pharmacy students’ understanding of off-label drug applications and identified strengths and weaknesses among pharmacy graduates.

Labelling 524
article thumbnail

Off-label treatment for alcohol use disorder is linked to slower liver decline, study suggests

STAT

But a different medication, one frequently used off-label for the condition, could provide greater benefit to patients with alcohol-associated liver disease, a new study suggests.    The data, presented this week as an abstract at Digestive Disease Week in D.C.,

Labelling 135
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs

The FDA Law Blog

Leading FDAs policy implementation of the MODERN Labeling Act , the statutory authority allowing FDA to make certain generic drug labeling updates. Since the inception of the program, DPD reportedly met every GDUFA goal date for timely issuance of a CPA. But thats all in the past now.

FDA 144
article thumbnail

Obesity Medication Use Remains Low Among Children | ADA 2025

Drug Topics

Despite a high prevalence of childhood and youth-aged obesity, the use of medications for treating obesity is persistently low among children and young adults (YA), according to an abstract presented at the American Diabetes Association’s 85th Scientific Sessions, held in Chicago, Illinois, from June 20-23, 2025. of adolescents and 5.7%

article thumbnail

Biogen admits slow Aduhelm launch, as scientists question label again

pharmaphorum

The agency – which originally cleared the drug for all Alzheimer’s patients but narrowed its label to the population studied in clinical trials after an outcry, is currently under investigation by lawmakers in the US. Shares in Biogen closed down a little under 7% yesterday after the presentation.

article thumbnail

Opinion: Diagnostic tests for rare conditions present a mathematical conundrum

STAT

Consequently, such “LDTs” can be quickly brought to market without the FDA review of their effectiveness, labeling accuracy, and marketing claims required for regular tests. Read the rest…

Labelling 130
article thumbnail

Dupixent improves symptoms in patients with skin of colour, study shows

Pharmafile

Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at the Revolutionizing Atopic Dermatitis Conference, Nashville, US, on 7 June, highlighting the impact of Dupixent (dupilumab) in patients with moderate-to-severe atopic dermatitis (AD) and skin of colour.